Rollins, Inc. Announces Closing of Secondary Public Offering of Common Stock
Get Alerts ROL Hot Sheet
Join SI Premium – FREE
Rollins did not sell any shares and did not receive any proceeds from the Offering.
In connection with the Offering, the Selling Stockholder entered into a lock-up agreement for a period of 365 days from the pricing date of the Offering, during which time the Selling Stockholder will be restricted from engaging in certain transactions with respect to its shares of the Company's common stock.
In addition, the Company completed the repurchase of 8,724,100 of the shares of common stock being offered in the Offering for approximately
Goldman Sachs & Co. LLC and Morgan Stanley acted as joint book-running managers for the Offering. BofA Securities acted as passive bookrunner for the Offering.
J.P. Morgan acted as Capital Markets Advisor to the Company.
The Offering was made pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Rollins, Inc.
Rollins, Inc. (ROL) is a premier global consumer and commercial services company. Through its family of leading brands, the Company and its franchises provide essential pest control services and protection against termite damage, rodents, and insects to more than 2.8 million customers in
Contact
Investor Relations
[email protected]
(404) 888-2000
View original content:https://www.prnewswire.com/news-releases/rollins-inc-announces-closing-of-secondary-public-offering-of-common-stock-301923774.html
SOURCE ROLLINS, INC.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
- FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
- Klarna CEO buys ~$10M in company shares
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
William Blair, JPMorgan, Goldman Sachs, Morgan Stanley, RBC Capital, Perella Weinberg, S3, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share